Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6086)	4/4/2002 10:25:07 AM
From: tuck	Read Replies (2) \| Respond to of 52153

Anyone have comments on the specificity and sensitivity shown in these results? >>FREMONT, Calif., April 4 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - news) today announced that more than two dozen studies involving its proprietary SELDI ProteinChip® Technology for the early detection of many different cancers will be presented during the American Association for Cancer Research (AACR) 93rd meeting in San Francisco, April 7-10. By using Ciphergen's SELDI ProteinChip Technology, these studies have identified multiple biomarkers and biomarker patterns that reveal protein expression associated with the early detection of cancer. Leading clinical researchers from around the world will present at AACR data generated using ProteinChip Systems that show impressive rates of cancer detection including sensitivities (true positives) ranging from 68-100% and specificities (true negatives)ranging from 81-96%. Users of SELDI ProteinChip Technology who will be presenting this week include Johns Hopkins University, M.D. Anderson Cancer Center, Mt. Sinai School of Medicine, Eastern Virginia Medical School, Lawrence Livermore National Laboratory, FDA, NCI, Brigham & Women's Hospital, Moffitt Cancer Center and others. Highlights of selected papers to be presented at AACR include: Cancer Study Sensitivity Specificity Institution Ovarian 94-100% 96% NCI, FDA, Northwestern Prostate 93.3% 93.8% Eastern Virginia Medical School Breast 92% 82% Johns Hopkins Medical School Liver 92.5% 90% Chinese University of Hong Kong Bladder 79% 81% Eastern Virginia Medical School ``We are very excited about the results coming out of leading medical research centers, both from their internal research programs and through their collaborations with Ciphergen scientists,'' said William Rich, Ph.D., President and CEO of Ciphergen. ``The 25 abstracts being presented at the AACR this year underscore the progress our customers are making in the area of early detection of cancer, and at the same time further validate Ciphergen's proprietary SELDI ProteinChip platform as the leading technology for biomarker discovery and pattern research.'' Dr. George L. Wright, who leads the cancer research effort at Eastern Virginia Medical School and is a Principal Investigator in the Early Detection Research Network funded by the National Cancer Institute, added, ``As researchers continue to unravel the complexities of disease processes, it has become increasingly apparent that future diagnostics will go beyond correlating a single protein to a disease, and instead will look at characteristic protein patterns to diagnose and infer disease progression. Ciphergen's technology offers researchers an extremely promising approach to detect the early onset of cancer.'' When compared to a single biomarker, multiple biomarkers offer significantly increased statistical power and superior predictive value for greater utility in diagnosis, toxicology, patient stratification and patient monitoring. Until recently, scientists lacked the tools to rapidly produce large sets of multiple-protein expression data for comparative analysis. With the recent release of Ciphergen's ProteinChip Biomarker System, clinical researchers are now collecting reproducible protein expression data on hundreds of proteins at once -- opening the door to rapid, simplified multiple pattern analysis.<< snip Stock ran up a bit when the AACR abstracts first became available, then dropped back. This morning, it's hardly moving. TIA & Cheers, Tuck